Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 472 Jan 1 – Oct 24, 2026
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| TB Terremoto BiosciencesCompany profile Develops highly targeted, small molecule medicines for cancer and rare diseases Develops highly targeted, small molecule medicines for cancer and rare diseases | $108M | Series CSeries C+ | Biotech | United States | Investors | |
| AT Alloy TherapeuticsCompany profile Drug discovery platforms and integrated development services for biotechnology and pharmaceutical partners. Drug discovery platforms and integrated development services for biotechnology and pharmaceutical partners. | $40M | Series ESeries C+ | Biotech | United States | Investors | |
| ST Develops non-invasive HIFU therapy system for cancer treatment | $18M | Series A | Biotech, Healthtech | United States | Investors | |
| ST Develops novel therapies for inner ear disorders | $27M | Series B | Biotech | United States | Investors | |
| CF Develops sustainable oils and fats through fermentation | £4.5M | Undisclosed | Biotech, Foodtech | United Kingdom | Investors | |
| H Develops virtual AI lab for pharmaceutical research and development | $10M | Seed | Biotech | Luxembourg | Investors | |
| A AdcendoCompany profile Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma. Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma. | $75M | Series CSeries C+ | Biotech | Denmark | Investors | |
| L LightcastCompany profile Develops functional single-cell analysis tools and platforms for life science research Develops functional single-cell analysis tools and platforms for life science research | $27M | Undisclosed | Biotech | United Kingdom | Investors | |
| QB Develops therapeutics for central nervous system disorders | Undisclosed | StrategicUndisclosed | Biotech | United States | Investors | |
| VT Develops extrahepatic RNA-targeting therapeutics | $54M | Series A | Biotech | China | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.